Montoya-Cerrillo Diego M, Evans Mark G, Elliott Andrew, Anyosa Renzo Calderon, Torres Jaylou Velez, Montgomery Elizabeth A, Hornicek Francis J, Temple H Thomas, Crawford Brooke, Trent Jonathan, Jonczak Emily E, D'Amato Gina, Rosenberg Andrew E
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Caris Life Sciences, Irving, Texas, USA.
Genes Chromosomes Cancer. 2025 Sep;64(9):e70068. doi: 10.1002/gcc.70068.
Conventional and dedifferentiated chondrosarcoma encompass a group of malignant neoplasms that produce cartilaginous matrix and arise within or on the surface of bone. Conventional chondrosarcomas are graded on a three-tiered scale, whereas dedifferentiated chondrosarcoma is typically not graded but is considered a high-grade sarcoma and represents the most aggressive subtype with a poor prognosis. IDH1 (isocitrate dehydrogenase-1) and IDH2 (isocitrate dehydrogenase-2) are the most commonly mutated genes in conventional and dedifferentiated chondrosarcoma, followed in frequency by COL2A1 and TP53. IDH1/2 driver mutations are also commonly found in enchondroma, considered a benign precursor lesion of chondrosarcoma, and other malignancies such as gliomas, cholangiocarcinoma, and acute myeloid leukemia. In acute myeloid leukemia, the presence of concurrent BCOR (BCL-6 corepressor) loss-of-function mutations has been linked to disease relapse and resistance to treatment with IDH inhibitors. After identifying an index case of conventional chondrosarcoma with unusually aggressive clinical evolution, we investigated the clinicopathological features of 12 cases of BCOR-mutated conventional and dedifferentiated chondrosarcomas against a control group of 15 BCOR-wildtype (WT) cases to determine whether BCOR-mutated tumors had patterns of biological progression different from tumors with intact BCOR. All identified BCOR alterations led to loss-of-function by either missense or nonsense mutations. The prevalence of BCOR mutations occurred in 5% of conventional and dedifferentiated chondrosarcoma, and these were associated with larger tumor size (p = 0.024), metastasis at the time of diagnosis (p ≤ 0.001) and higher T category (3-4 vs. 1-2) (p = 0.009). Although larger studies are necessary to clarify the full impact of BCOR mutations on patients with conventional and dedifferentiated chondrosarcoma, our data indicate that BCOR genetic aberrations are associated with adverse clinical features.
传统型和去分化型软骨肉瘤是一组产生软骨基质且起源于骨内或骨表面的恶性肿瘤。传统型软骨肉瘤按三级标准分级,而去分化型软骨肉瘤通常不分级,但被视为高级别肉瘤,是预后最差、最具侵袭性的亚型。异柠檬酸脱氢酶1(IDH1)和异柠檬酸脱氢酶2(IDH2)是传统型和去分化型软骨肉瘤中最常发生突变的基因,其次是Ⅱ型胶原基因(COL2A1)和抑癌基因(TP53)。IDH1/2驱动突变在软骨瘤(被认为是软骨肉瘤的良性前驱病变)以及其他恶性肿瘤(如神经胶质瘤、胆管癌和急性髓系白血病)中也很常见。在急性髓系白血病中,同时存在BCOR(BCL-6共抑制因子)功能丧失性突变与疾病复发及对IDH抑制剂治疗的耐药性有关。在确定了1例临床进展异常侵袭性的传统型软骨肉瘤索引病例后,我们针对15例BCOR野生型(WT)病例的对照组,研究了12例BCOR突变的传统型和去分化型软骨肉瘤的临床病理特征,以确定BCOR突变肿瘤是否具有与BCOR完整的肿瘤不同的生物学进展模式。所有鉴定出的BCOR改变均通过错义或无义突变导致功能丧失。BCOR突变在5%的传统型和去分化型软骨肉瘤中出现,这些突变与更大的肿瘤大小(p = 0.024)、诊断时的转移(p≤0.001)以及更高的T分期(3 - 4期 vs. 1 - 2期)(p = 0.009)相关。尽管需要更大规模的研究来阐明BCOR突变对传统型和去分化型软骨肉瘤患者的全面影响,但我们的数据表明BCOR基因畸变与不良临床特征相关。